Timber Pharmaceuticals Inc

ASE:TMBR 3:59:48 PM EDT

0.31

+0.01 (+2.81%)

Products

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation For TMB-001 For The Treatment Of Congenital Ichthyosis

Published: 05/31/2022 13:45 GMT

Timber Pharmaceuticals Inc (TMBR) - Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Tmb-001 for the Treatment of Congenital Ichthyosis.
Timber Pharmaceuticals Inc - Company Preparing to Dose First Patients in Pivotal Phase 3 Ascend Clinical Trial.